Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials

[31] Schuetz P(2013)Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients Crit Care 17 R115-2602

[32] Birkhahn R(2013)Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia Curr Opin Infect Dis 26 159-1184

[33] Sherwin R(2010)Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial JAMA 303 739-21

[34] Jones AE(2015)Procalcitonin: an effective screening tool and safe therapeutic decision making aid for emergency department patients with suspected sepsis Ann Emerg Med 66 318-40

[35] Singer A(2014)Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes Intensive Care Med 40 141-129

[36] Kline JA(2012)Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis Clin Infect Dis 55 651-undefined

[37] Runyon MS(2018)Reassessment of a meta-analysis of procalcitonin-guided antibiotic therapy for lower respiratory tract infections—authors’ reply Lancet Infect Dis 18 141-undefined

[38] Self WH(2006)Procalcitonin increase in early identification of critically ill patients at high risk of mortality Crit Care Med 34 2596-undefined

[39] Courtney DM(2009)Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship Clin Infect Dis 49 1175-undefined

[40] Nowak RM(2010)Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance Jt Comm J Qual Patient Saf 36 12-undefined

[31] Schuetz P(2013)Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients Crit Care 17 R115-2602

[32] Birkhahn R(2013)Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia Curr Opin Infect Dis 26 159-1184

[33] Sherwin R(2010)Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial JAMA 303 739-21

[34] Jones AE(2015)Procalcitonin: an effective screening tool and safe therapeutic decision making aid for emergency department patients with suspected sepsis Ann Emerg Med 66 318-40

[35] Singer A(2014)Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes Intensive Care Med 40 141-129

[36] Kline JA(2012)Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis Clin Infect Dis 55 651-undefined

[37] Runyon MS(2018)Reassessment of a meta-analysis of procalcitonin-guided antibiotic therapy for lower respiratory tract infections—authors’ reply Lancet Infect Dis 18 141-undefined

[38] Self WH(2006)Procalcitonin increase in early identification of critically ill patients at high risk of mortality Crit Care Med 34 2596-undefined

[39] Courtney DM(2009)Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship Clin Infect Dis 49 1175-undefined

[40] Nowak RM(2010)Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance Jt Comm J Qual Patient Saf 36 12-undefined